Precipio, Inc. (PRPO)
USD 5.56
(-3.81%)
USD 5.56
(-3.81%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.01 Million USD | 79.32% |
| 2022 | 2.51 Million USD | 4.93% |
| 2021 | 2.39 Million USD | 108.0% |
| 2020 | 1.15 Million USD | 425.11% |
| 2019 | 219 Thousand USD | -2.67% |
| 2018 | 225 Thousand USD | -22.95% |
| 2017 | 292 Thousand USD | 242.44% |
| 2016 | -205 Thousand USD | 28.57% |
| 2015 | -287 Thousand USD | -102.95% |
| 2014 | 9.72 Million USD | -22.21% |
| 2013 | 12.49 Million USD | -16.75% |
| 2012 | 15.01 Million USD | -18.59% |
| 2011 | 18.43 Million USD | 88.83% |
| 2010 | 9.76 Million USD | -15.86% |
| 2009 | 11.6 Million USD | -14.97% |
| 2008 | 13.64 Million USD | 7.52% |
| 2007 | 12.69 Million USD | 11.65% |
| 2006 | 11.36 Million USD | -7.8% |
| 2005 | 12.33 Million USD | 34.13% |
| 2004 | 9.19 Million USD | -3.75% |
| 2003 | 9.55 Million USD | -46.89% |
| 2002 | 17.98 Million USD | -15.44% |
| 2001 | 21.26 Million USD | 41.88% |
| 2000 | 14.99 Million USD | 20.32% |
| 1999 | 12.45 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.41 Million USD | 54.24% |
| 2024 Q1 | 920 Thousand USD | -44.0% |
| 2023 Q1 | 749 Thousand USD | 25.25% |
| 2023 FY | 4.5 Million USD | 79.32% |
| 2023 Q4 | 1.64 Million USD | -12.84% |
| 2023 Q3 | 1.88 Million USD | 37.49% |
| 2023 Q2 | 1.37 Million USD | 83.04% |
| 2022 Q2 | 773 Thousand USD | 9.96% |
| 2022 FY | 2.51 Million USD | 4.93% |
| 2022 Q3 | 436 Thousand USD | -43.6% |
| 2022 Q4 | 598 Thousand USD | 37.16% |
| 2022 Q1 | 703 Thousand USD | 8.99% |
| 2021 FY | 2.39 Million USD | 108.0% |
| 2021 Q2 | 751 Thousand USD | 60.47% |
| 2021 Q3 | 528 Thousand USD | -29.69% |
| 2021 Q4 | 645 Thousand USD | 22.16% |
| 2021 Q1 | 468 Thousand USD | -1.89% |
| 2020 Q2 | 171 Thousand USD | 36.8% |
| 2020 FY | 1.15 Million USD | 425.11% |
| 2020 Q3 | 377 Thousand USD | 120.47% |
| 2020 Q4 | 477 Thousand USD | 26.53% |
| 2020 Q1 | 125 Thousand USD | 757.89% |
| 2019 FY | 219 Thousand USD | -2.67% |
| 2019 Q1 | 38 Thousand USD | 2.7% |
| 2019 Q2 | 172 Thousand USD | 352.63% |
| 2019 Q3 | 28 Thousand USD | -83.72% |
| 2019 Q4 | -19 Thousand USD | -167.86% |
| 2018 Q1 | 24 Thousand USD | -92.66% |
| 2018 FY | 225 Thousand USD | -22.95% |
| 2018 Q4 | 37 Thousand USD | 436.36% |
| 2018 Q3 | -11 Thousand USD | -106.29% |
| 2018 Q2 | 175 Thousand USD | 629.17% |
| 2017 FY | 292 Thousand USD | 242.44% |
| 2017 Q1 | 199 Thousand USD | 168.92% |
| 2017 Q2 | -24 Thousand USD | -112.06% |
| 2017 Q4 | 327 Thousand USD | 524.68% |
| 2017 Q3 | -77 Thousand USD | -220.83% |
| 2016 Q2 | -37 Thousand USD | 86.25% |
| 2016 Q4 | 74 Thousand USD | 174.07% |
| 2016 FY | -205 Thousand USD | 28.57% |
| 2016 Q1 | -269 Thousand USD | 96.28% |
| 2016 Q3 | 27 Thousand USD | 172.97% |
| 2015 Q3 | 1.76 Million USD | -38.58% |
| 2015 FY | -287 Thousand USD | -102.95% |
| 2015 Q2 | 2.87 Million USD | -3.43% |
| 2015 Q1 | 2.97 Million USD | 13.55% |
| 2015 Q4 | -7.22 Million USD | -509.58% |
| 2014 Q2 | 2.39 Million USD | -4.05% |
| 2014 FY | 9.72 Million USD | -22.21% |
| 2014 Q1 | 2.49 Million USD | -2.35% |
| 2014 Q4 | 2.61 Million USD | 18.24% |
| 2014 Q3 | 2.21 Million USD | -7.44% |
| 2013 FY | 12.49 Million USD | -16.75% |
| 2013 Q4 | 2.55 Million USD | -10.42% |
| 2013 Q2 | 3.41 Million USD | -7.36% |
| 2013 Q3 | 2.85 Million USD | -16.39% |
| 2013 Q1 | 3.68 Million USD | 3.87% |
| 2012 Q3 | 3.8 Million USD | -16.7% |
| 2012 Q4 | 3.54 Million USD | -6.74% |
| 2012 Q2 | 4.56 Million USD | 46.97% |
| 2012 Q1 | 3.1 Million USD | -41.27% |
| 2012 FY | 15.01 Million USD | -18.59% |
| 2011 Q4 | 5.28 Million USD | 18.9% |
| 2011 Q3 | 4.44 Million USD | -2.41% |
| 2011 Q2 | 4.55 Million USD | 9.65% |
| 2011 Q1 | 4.15 Million USD | 74.83% |
| 2011 FY | 18.43 Million USD | 88.83% |
| 2010 Q3 | 2.01 Million USD | -18.9% |
| 2010 Q4 | 2.37 Million USD | 17.8% |
| 2010 Q2 | 2.48 Million USD | -13.77% |
| 2010 FY | 9.76 Million USD | -15.86% |
| 2010 Q1 | 2.88 Million USD | -14.88% |
| 2009 FY | 11.6 Million USD | -14.97% |
| 2009 Q1 | 2.81 Million USD | -16.0% |
| 2009 Q4 | 3.38 Million USD | 23.07% |
| 2009 Q3 | 2.75 Million USD | 3.85% |
| 2009 Q2 | 2.65 Million USD | -5.76% |
| 2008 Q2 | 3.73 Million USD | 2.72% |
| 2008 Q1 | 3.64 Million USD | -7.14% |
| 2008 Q3 | 2.91 Million USD | -21.93% |
| 2008 Q4 | 3.34 Million USD | 14.73% |
| 2008 FY | 13.64 Million USD | 7.52% |
| 2007 Q3 | 2.65 Million USD | -22.33% |
| 2007 Q1 | 2.7 Million USD | -10.48% |
| 2007 FY | 12.69 Million USD | 11.65% |
| 2007 Q4 | 3.92 Million USD | 47.87% |
| 2007 Q2 | 3.41 Million USD | 26.03% |
| 2006 Q4 | 3.02 Million USD | 30.84% |
| 2006 Q2 | 3.04 Million USD | 2.25% |
| 2006 Q3 | 2.31 Million USD | -24.17% |
| 2006 Q1 | 2.98 Million USD | 33.78% |
| 2006 FY | 11.36 Million USD | -7.8% |
| 2005 FY | 12.33 Million USD | 34.13% |
| 2005 Q2 | 3.18 Million USD | 7.06% |
| 2005 Q3 | 3.94 Million USD | 23.94% |
| 2005 Q4 | 2.22 Million USD | -43.5% |
| 2005 Q1 | 2.97 Million USD | 61.31% |
| 2004 Q2 | 3.15 Million USD | 10.21% |
| 2004 Q3 | 1.33 Million USD | -57.6% |
| 2004 Q4 | 1.84 Million USD | 37.85% |
| 2004 FY | 9.19 Million USD | -3.75% |
| 2004 Q1 | 2.86 Million USD | 13.08% |
| 2003 Q2 | 2.55 Million USD | -30.75% |
| 2003 Q3 | 775 Thousand USD | -69.68% |
| 2003 Q4 | 2.53 Million USD | 226.45% |
| 2003 Q1 | 3.69 Million USD | -1.34% |
| 2003 FY | 9.55 Million USD | -46.89% |
| 2002 Q2 | 4.86 Million USD | -4.82% |
| 2002 Q4 | 3.74 Million USD | -11.96% |
| 2002 Q1 | 5.1 Million USD | -13.93% |
| 2002 FY | 17.98 Million USD | -15.44% |
| 2002 Q3 | 4.24 Million USD | -12.61% |
| 2001 Q4 | 5.93 Million USD | 4.8% |
| 2001 FY | 21.26 Million USD | 41.88% |
| 2001 Q1 | 4.26 Million USD | 1.1% |
| 2001 Q2 | 5.4 Million USD | 26.86% |
| 2001 Q3 | 5.66 Million USD | 4.72% |
| 2000 FY | 14.99 Million USD | 20.32% |
| 2000 Q1 | 3.61 Million USD | 0.0% |
| 2000 Q2 | 3.36 Million USD | -6.86% |
| 2000 Q3 | 3.73 Million USD | 10.86% |
| 2000 Q4 | 4.21 Million USD | 13.03% |
| 1999 FY | 12.45 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | 37.09% |
| Prenetics Global Limited | 8.82 Million USD | 31.845% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 49.539% |
| CareDx, Inc | 178.32 Million USD | 96.625% |
| Exact Sciences Corporation | 1.84 Billion USD | 99.674% |
| Exagen Inc. | 29.45 Million USD | 79.57% |
| Inotiv, Inc. | 165.44 Million USD | 96.362% |
| Guardant Health, Inc. | 336.89 Million USD | 98.214% |
| Biodesix, Inc. | 36.07 Million USD | 83.319% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | -352.652% |
| iSpecimen Inc. | 5.1 Million USD | -17.817% |
| Natera, Inc. | 492.74 Million USD | 98.779% |
| Aspira Women's Health Inc. | 5.26 Million USD | -14.367% |
| Standard BioTools Inc. | 50.45 Million USD | 88.071% |
| 23andMe Holding Co. | 99.37 Million USD | 93.944% |
| Castle Biosciences, Inc. | 174.8 Million USD | 96.557% |
| Personalis, Inc. | 18.2 Million USD | 66.949% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | 54.298% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | -8.757% |
| OpGen, Inc. | -90.69 Thousand USD | 6735.5% |
| T2 Biosystems, Inc. | -8.17 Million USD | 173.66% |
| Myriad Genetics, Inc. | 476.4 Million USD | 98.737% |
| ICON Public Limited Company | 1.81 Billion USD | 99.668% |
| NeoGenomics, Inc. | 244.6 Million USD | 97.54% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 49.539% |
| IDEXX Laboratories, Inc. | 2.18 Billion USD | 99.725% |
| RadNet, Inc. | 93 Million USD | 93.529% |
| MDxHealth SA | 43.92 Million USD | 86.301% |
| Psychemedics Corporation | 8.41 Million USD | 28.468% |
| Illumina, Inc. | 2.74 Billion USD | 99.781% |
| Check-Cap Ltd. | -212 Thousand USD | 2938.679% |
| Twist Bioscience Corporation | 133.34 Million USD | 95.487% |
| DarioHealth Corp. | 5.98 Million USD | -0.568% |
| Fulgent Genetics, Inc. | 104.45 Million USD | 94.239% |
| Sera Prognostics, Inc. | 96 Thousand USD | -6168.75% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 2284.781% |
| OPKO Health, Inc. | 318.12 Million USD | 98.108% |
| Medpace Holdings, Inc. | 524.5 Million USD | 98.853% |
| Neogen Corporation | 463.9 Million USD | 98.703% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | -322.13% |
| Prenetics Global Limited | 8.82 Million USD | 31.845% |
| Mainz Biomed B.V. | 509.65 Thousand USD | -1080.79% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -660.218% |
| Trinity Biotech plc | 19.45 Million USD | 69.059% |
| Neuronetics, Inc. | 51.7 Million USD | 88.361% |
| Sotera Health Company | 577.15 Million USD | 98.957% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -660.218% |